ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant.

A. Vo, J. Choi, I. Kim, E. Huang, S. Louie, A. Kang, S. Williamson, K. Myers, A. Peng, R. Najjar, S. Jordan.

Kidney Transplant, Cedars-Sinai Medical Center, LA, CA

Meeting: 2017 American Transplant Congress

Abstract number: 108

Keywords: Highly-sensitized, HLA antibodies, Monoclonal antibodies, Rejection

Session Information

Session Name: Concurrent Session: Clinical Science: Kidney Immunosuppression: Desensitization

Session Type: Concurrent Session

Date: Sunday, April 30, 2017

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:30pm-5:42pm

Location: E354b

INTRODUCTION: ~30% of HS patients fail to respond to DES with IVIG+rituximab. IL6/IL-6R signaling is critical for B-cell differentiation to plasmablasts and IgG production. Tocilizumab (TCZ) is a 1st in-class monoclonal directed at the IL-6R. TCZ treatment in humans inhibits TFH & Th17 cells while increasing Tregs and suppressing plasmablasts. We previously reported on the efficacy of TCZ as a DES agent. Here we report our extended experience using DES with PLEX+IVIG+TCZ. PATIENTS & METHODS: From 12/7/10 – 6/29/16, 26 HS patients were DES with PLEX+IVIG+TCZ. Acceptable crossmatch criteria included: negative CDC-CMX, FCMX ≤225MCS and DSA ≤10,000MFI post-DES. Unacceptable antigens were defined as MFI>15000. Transplanted patients received induction with alemtuzumab and maintained with tac/mmf/pred + monthly TCZ x6M. Patient & graft survival, eGFR, freedom from ABMR and change in DSA levels post-TCZ were analyzed. RESULTS: Ten patients did not achieve DSA reduction sufficient for transplantation after TCZ. All had previous transplants and multiple C1Q+ HLA specificities with CPRA 99-100% {G1}. However, 16 patients were transplanted after TCZ DES {G2}. Briefly, 11 patients were FCMX+/DSA+ @transplant. Three patients developed ABMR post-transplant, but responded to PLEX/IVIG/Ritux and continuation of TCZ X 6M (Figure 1). A significant reduction in DSA from pre- to post-transplant was seen in TCZ treated patients (P<0.03) (Figure 2). Patient & graft survival up to 36M was 100%. Mean time to transplant from 1st DES was 28±17.5M. However, after TCZ,was 4±3.3M. Finally, eGFR were similar at 12M, 24M & 36M (~57±21 ml/min/1.73m2). CONCLUSIONS: 26 patients were DES with TCZ. Sixteen patients received incompatible transplants with no patient or graft loss. Three patients developed ABMR, usually after cessation of TCZ therapy. TCZ DES resulted in significant reduction of DSA post-transplant. Therefore, TCZ may offer benefit in improving rates of transplant for HS patients who fail to respond to IVIG+rituximab therapy and benefits in maintaining the allograft long-term. [figure2]

CITATION INFORMATION: Vo A, Choi J, Kim I, Huang E, Louie S, Kang A, Williamson S, Myers K, Peng A, Najjar R, Jordan S. Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Vo A, Choi J, Kim I, Huang E, Louie S, Kang A, Williamson S, Myers K, Peng A, Najjar R, Jordan S. Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/extended-experience-with-tocilizumab-anti-il6r-for-difficult-to-desensitize-des-patients-awaiting-hla-incompatible-kidney-transplant/. Accessed June 3, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences